FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease

The U.S. Food and Drug Administration (FDA) has granted approval to Auvelity (dextromethorphan-bupropion), marking a significant advancement in the management of agitation associated with Alzheimer’s disease. This approval introduces the first and only FDA-sanctioned treatment for Alzheimer’s-related agitation that is not classified as an antipsychotic, addressing a critical unmet medical need for millions of patients and their caregivers. The decision, announced recently, has been widely welcomed by patient advocacy groups, clinicians, and the pharmaceutical industry, heralding a new era in the holistic care of individuals living with this progressive neurodegenerative disorder.

The Pervasive Challenge of Alzheimer’s Agitation

Alzheimer’s disease, a relentless and irreversible neurodegenerative condition, is primarily characterized by progressive memory loss and cognitive decline. However, beyond its profound impact on cognitive functions, a significant proportion of individuals with Alzheimer’s also experience a range of neuropsychiatric symptoms, collectively known as Behavioral and Psychological Symptoms of Dementia (BPSD). Among these, agitation stands out as one of the most prevalent, distressing, and challenging aspects of the disease, affecting an estimated three-quarters of all Alzheimer’s patients at some point during their illness.

Agitation in Alzheimer’s can manifest in various forms, ranging from restlessness, pacing, and repetitive verbalizations to more disruptive behaviors such as physical or verbal aggression, combativeness, and uncooperativeness. These symptoms not only severely diminish the patient’s quality of life, leading to increased distress, confusion, and fear, but also place an immense burden on caregivers. Families often grapple with feelings of helplessness, exhaustion, and emotional strain, with agitation being a leading cause of caregiver burnout, early institutionalization in assisted living or long-term care facilities, and increased healthcare costs. Experts like Jeffrey Cummings, MD, a professor in the Kirk Kerkorian School of Medicine at the University of Nevada, Las Vegas, emphasize that agitation is "among the most burdensome aspects of the disease for patients and families," correlating with "accelerated cognitive decline, placement in assisted living and long-term care facilities, and increased mortality risk." For decades, the therapeutic landscape for Alzheimer’s-related agitation has been alarmingly limited, primarily relying on off-label use of antipsychotic medications, which, while sometimes effective in symptom suppression, carry substantial risks.

The Historical Limitations of Treatment Options

Prior to Auvelity’s approval, clinicians often resorted to prescribing antipsychotics to manage severe agitation in Alzheimer’s patients. While these drugs can help control acute behavioral disturbances, their use in elderly patients with dementia is fraught with significant safety concerns. The FDA has issued "black box" warnings for antipsychotics, highlighting an increased risk of death in elderly patients with dementia-related psychosis, primarily due to cardiovascular events (such as heart failure and sudden death) and infections (like pneumonia). Other serious side effects include sedation, falls, and cerebrovascular events (strokes or mini-strokes). These risks have made the medical community hesitant to use antipsychotics unless absolutely necessary, leaving a gaping void in safe and effective treatment options for chronic agitation.

Joanne Pike, president and CEO of the Alzheimer’s Association, articulated this long-standing dilemma, stating, "For too long, people living with Alzheimer’s disease agitation and their families have had limited options, and the options that existed came with significant risks." The approval of Auvelity, therefore, represents not just an incremental step but a transformative leap, offering a non-antipsychotic alternative that could profoundly alter the treatment paradigm for this debilitating symptom.

Auvelity: A Novel Mechanism of Action

Developed by Axsome Therapeutics, Auvelity, previously known as AXS-05, is a novel oral medication that distinguishes itself through its unique dual mechanism of action. It combines dextromethorphan, an N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, with bupropion, an aminoketone antidepressant that also serves as a cytochrome P450 2D6 (CYP2D6) enzyme inhibitor.

The active component, dextromethorphan, is known for its role in modulating the activity of two key brain cell receptors: the NMDA receptor and the sigma-1 receptor. Dysregulation of these receptors is implicated in various neurological and psychiatric conditions, including depression and potentially the neuropsychiatric symptoms seen in Alzheimer’s. By modulating these receptors, Auvelity is designed to regulate brain activity and alleviate agitation. Bupropion’s role in the combination is critical; it enhances the bioavailability of dextromethorphan by inhibiting its rapid metabolism by the CYP2D6 enzyme in the liver, allowing dextromethorphan to reach therapeutic levels in the brain and exert its intended effects. This synergistic combination provides a distinct pharmacological approach compared to traditional antipsychotics.

It is noteworthy that Auvelity was already FDA-approved for the treatment of adults with major depressive disorder (MDD) in August 2022. This prior approval provides clinicians with some familiarity with the drug’s general safety profile and mechanism, potentially facilitating its adoption for the new indication in Alzheimer’s agitation.

A Rigorous Path to Approval: The Clinical Evidence

Axsome’s application for FDA approval of Auvelity for Alzheimer’s-related agitation was underpinned by a comprehensive battery of clinical trials, demonstrating its efficacy and safety. These included four Phase 3 studies: ACCORD (NCT04797715), ACCORD-2 (NCT04947553), ADVANCE-1 (NCT03226522), and ADVANCE-2 (NCT05557409), as well as a long-term extension study (NCT06736509) designed to monitor sustained outcomes.

The ADVANCE-1 and ADVANCE-2 studies were pivotal trials that directly compared Auvelity against a placebo in patients experiencing Alzheimer’s-related agitation. In the smaller ADVANCE-1 study, Auvelity showcased significant superiority over placebo in reducing agitation, as measured by scores on the Cohen-Mansfield Agitation Inventory (CMAI), a widely recognized standardized assessment tool for agitation in dementia. The CMAI assesses the frequency of 29 agitated behaviors, providing a quantitative measure of treatment effect. In the larger ADVANCE-2 study, while patients receiving Auvelity generally reported reductions in agitation compared to the placebo group, the difference did not achieve statistical significance. This outcome, though not statistically significant, still indicated a positive trend in symptom reduction, contributing to the overall body of evidence.

Crucially, the ACCORD and ACCORD-2 studies focused on the prevention of agitation relapse, a critical aspect of long-term management. In these studies, participants initially received Auvelity. Those who experienced a substantial reduction in agitation, as assessed by CMAI scores, were then randomized to either continue active therapy with Auvelity or switch to a placebo. The results from both studies were compelling: patients who switched to a placebo were significantly more likely to experience a recurrence of agitation symptoms compared to those who continued taking Auvelity. This finding underscores the drug’s ability to provide sustained relief and prevent relapse, a key differentiator in a field lacking long-term solutions. George Grossberg, MD, a professor at the Saint Louis University School of Medicine, highlighted this aspect, noting, "Auvelity is the only FDA-approved product to result in a statistically significantly longer time to relapse of agitation symptoms, compared to placebo, in a long-term study."

The collective data from these trials painted a picture of a medication that is not only effective in acutely reducing agitation but also in maintaining that reduction over time, thereby offering a more stable and predictable course of treatment for patients and caregivers.

Safety Profile and Patient Support Initiatives

Beyond efficacy, the safety and tolerability profile of Auvelity was a crucial consideration for its approval. According to the prescribing information, the most common side effects observed in Alzheimer’s patients treated with Auvelity were dyspepsia (indigestion) and dizziness. Importantly, the clinical trials demonstrated a "compelling safety and tolerability profile," with rates of discontinuation due to adverse events being low and comparable to those observed with placebo. This favorable tolerability profile is particularly significant given the vulnerability of the elderly Alzheimer’s population to adverse drug reactions.

As with many medications approved to treat depression, Auvelity’s prescribing information includes a black box warning, the FDA’s most stringent safety warning. This warning notes that the use of antidepressants can increase the risk of suicidal thoughts and behaviors in young people. It is important to contextualize this warning: it is a class effect for antidepressants and not specific to Auvelity’s use in Alzheimer’s disease for increased suicidal risk in that particular population. The FDA mandates this warning for all drugs in the antidepressant class due to observed risks in children, adolescents, and young adults (up to 24 years of age) with major depressive disorder and other psychiatric disorders. Clinicians are advised to carefully weigh these risks, particularly when prescribing to younger patients.

Axsome Therapeutics has also announced plans to launch a patient support program called Auvelity OnMySide concurrently with the commercial launch of the new medication. This program is designed to provide comprehensive resources, including financial aid and insurance assistance, for eligible patients, aiming to improve access and affordability. Such support initiatives are vital for ensuring that innovative treatments reach those who need them most, alleviating potential financial barriers that can hinder adherence and overall treatment success.

Expert Perspectives and Broader Implications

The approval of Auvelity has been met with widespread optimism within the medical and patient advocacy communities. Herriot Tabuteau, MD, CEO of Axsome Therapeutics, emphasized the significance of this milestone, stating, "The approval of our first-in-class medication for agitation associated with Alzheimer’s disease marks an important milestone for the millions of patients living with Alzheimer’s disease, their families, and their caregivers. We are very pleased to deliver to clinicians and patients a new, effective, FDA-approved treatment option, with a distinct mechanism of action, for this debilitating and critically underserved condition."

Joanne Pike of the Alzheimer’s Association underscored the practical impact: "This approval gives patients, caregivers and clinicians an important new tool — one that works through a different mechanism than antipsychotic medications and that can help address a symptom that profoundly affects quality of life for people living with Alzheimer’s and those who care for them.” This sentiment highlights the dual benefit for both those living with the disease and their dedicated support networks.

From an independent expert perspective, Frank Longo, MD, PhD, a professor of neurology at Stanford University and co-founder of Pharmatrophix, noted that the FDA’s approval "highlights the advances being made in addressing the day-to-day realities of the disease." He added that "for patients and caregivers, any progress in Alzheimer’s treatment is meaningful. This milestone… reflects the growing momentum in innovative treatments for neurodegenerative diseases and further underscores the continued need for disease-modifying therapies." Dr. Longo’s comments provide a balanced view, acknowledging the importance of symptomatic treatments like Auvelity while also emphasizing the ongoing pursuit of therapies that can alter the underlying course of Alzheimer’s disease itself.

The introduction of a non-antipsychotic treatment for Alzheimer’s agitation carries profound implications. It offers clinicians a safer alternative, potentially reducing the reliance on drugs with a less favorable risk-benefit profile in a vulnerable population. For patients, it means the possibility of experiencing less distress, improved comfort, and a better overall quality of life, allowing them to engage more meaningfully with their surroundings and loved ones. For caregivers, it translates to a potential reduction in the immense stress and burnout associated with managing agitated behaviors, offering a measure of relief and potentially delaying the need for institutional care.

Looking Ahead: A New Era for Alzheimer’s Care

The approval of Auvelity for Alzheimer’s-related agitation signifies a pivotal moment in the ongoing battle against this complex disease. It not only addresses a significant unmet medical need but also sets a precedent for the development of targeted, safer, and more effective treatments for the myriad neuropsychiatric symptoms that accompany dementia. While the search for disease-modifying therapies for Alzheimer’s continues, the ability to manage distressing symptoms like agitation effectively and safely marks a substantial improvement in patient care.

The impact of this approval extends beyond individual patients and caregivers, potentially influencing healthcare policies, treatment guidelines, and future research directions in the field of dementia care. It underscores a growing understanding that comprehensive Alzheimer’s care must encompass not only cognitive preservation but also the compassionate and effective management of behavioral symptoms that profoundly affect daily living. As Auvelity becomes commercially available, its real-world impact will be closely monitored, but the initial outlook is one of immense hope and optimism for millions affected by Alzheimer’s disease.